Global Multiple Myeloma Market Analysis, 2020

Growing R&D Investment and Approval for the Novel Drug Development Boosting the Global Multiple Myeloma Market Growth

Multiple Myeloma is type of cancer that develops in the plasma cells which affects the bone marrow of the body.

Global Multiple Myeloma Market Analysis, 2020 research report depicts a deep-dive market analysis of statistics of Global Multiple Myeloma market which consists of regional and country-wise market size, market forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end users, applications, product type, technologies, competitive benchmarking, etc.

According to this research report titled “Global Multiple Myeloma Market Analysis, 2020”, the Global Multiple Myeloma market is anticipated to grow at a CAGR of around 6% during 2020-25F. Laboratories segment acquired the considerable market share in the Multiple Myeloma market in 2019 owing to the rising investment by pharma companies for the research and development of novel drugs for the treatment.

Chemotherapy Acquired the Substantial Market Share

Based on Medication, chemotherapy acquired the substantial market share owing to the limited surgical procedures, absence of alternative medication along with ongoing development of several pipeline drugs in chemotherapy. Target therapy is also gaining robust pace in the market on an account of surging adoption of immunomodulating drugs coupled with the approval and launch of monoclonal antibodies, such as Empliciti and Darzalex in the market which is expected to proliferate the growth of the Multiple Myeloma market in the coming year as stated in the research report “Global Multiple Myeloma Market Analysis, 2020”.

According to the publisher, the key players with a considerable market share in the Global Multiple Myeloma market include Janssen Biotech, Bristol-Myers Squibb, Novartis, Celgene, Kesios Therapeutics, Amgen, Sanofi Genzyme, Juno Therapeutics, Takeda, Karyopharm etc.

Key Questions Answered in the Market Research Report

1. What are the key overall market statistics or market estimates (Market Overview, Market Size- By Value, Forecast Numbers, Market Segmentation, Market Shares) of Global Multiple Myeloma Market?
2. What is the region wise industry size, growth drivers and challenges key market trends?
3. What are the key innovations, technology upgrades, opportunities, regulations in the Global Multiple Myeloma Market?
4. Who are the key competitors or market players and how they perform in Global Multiple Myeloma Market based on competitive benchmarking matrix?
5. What are the key results derived from the market surveys conducted during the course of Global Multiple Myeloma Market study?

1. Introduction

1.1. Product Definition
1.2. Research Process
1.3. Market Segmentation
1.4. Assumptions

2. Executive Summary3. Global Multiple Myeloma Overview4. Global Multiple Myeloma Startups Ecosystem5. Impact of COVID-19 on Global Multiple Myeloma Market6. Expert Verbatim-Interview Excerpts of industry experts

7. Global Multiple Myeloma Market Outlook, 2015-2025

7.1. Market Size & Analysis
7.1.1. Revenues
7.2. Market Share & Analysis
7.2.1. By Test Type
7.2.1.1. Blood
7.2.1.2. Biopsy
7.2.1.3. Imaging
7.2.1.3.1. X-rays
7.2.1.3.2. CT scan (Computed tomography scan)
7.2.1.3.3. Magnetic resonance imaging (MRI) scans
7.2.1.3.4. Positron emission tomography (PET) scan
7.2.1.3.5. Echocardiogram (ECHO)
7.2.1.4. Others (Urine test, etc.)
7.2.2. By Medication
7.2.2.1. Chemotherapy
7.2.2.1.1. Anthracycline antiobiotic
7.2.2.1.2. Alkylating agent
7.2.2.2. Targeted Therapies
7.2.2.2.1. Immunomodulatory Drugs
7.2.2.2.2. Monoclonal Antibodies
7.2.2.2.3. Proteasome Inhibitors
7.2.2.2.4. Histone Deacetylase (HDAC) Inhibitors
7.2.2.2.5. Others (Nuclear export inhibitor,etc.)
7.2.2.3. Radiation Therapy
7.2.2.4. Stem Cell Transplant
7.2.2.5. Supportive Treatments
7.2.3. By End Users
7.2.3.1. Hospitals & Specialty Centers
7.2.3.2. Laboratories
7.2.3.3. Others
7.2.4. By Region
7.2.4.1. North America
7.2.4.2. South America
7.2.4.3. Europe
7.2.4.4. Middle East & Africa
7.2.4.5. Asia-Pacific
7.2.5. By Company
7.2.5.1. Market Shares, By Revenue
7.2.5.2. Strategic Factorial Indexing
7.2.5.3. Competitor Placement in MarkNtel Quadrant
7.3. Market Attractiveness Index
7.3.1. By Test Type
7.3.2. By Medication
7.3.3. By End Users
7.3.4. By Region

8. North America Multiple Myeloma Market Outlook, 2015-2025

8.1. Market Size & Analysis
8.1.1. Revenues
8.2. Market Share & Analysis
8.2.1. By Test Type
8.2.2. By Medication
8.2.3. By End Users
8.2.4. By Country
8.2.4.1. The US
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. The US Multiple Myeloma Market Outlook, 2015-2025
8.3.1. Market Size & Analysis
8.3.1.1. Revenues
8.3.2. Market Share & Analysis
8.3.2.1. By Test Type
8.3.2.2. By Medication
8.4. Canada Multiple Myeloma Market Outlook, 2015-2025
8.4.1. Market Size & Analysis
8.4.1.1. Revenues
8.4.2. Market Share & Analysis
8.4.2.1. By Test Type
8.4.2.2. By Medication
8.5. Mexico Multiple Myeloma Market Outlook, 2015-2025
8.5.1. Market Size & Analysis
8.5.1.1. Revenues
8.5.2. Market Share & Analysis
8.5.2.1. By Test Type
8.5.2.2. By Medication

9. South America Multiple Myeloma Market Outlook, 2015-2025

9.1. Market Size & Analysis
9.1.1. Revenues
9.2. Market Share & Analysis
9.2.1. By Test Type
9.2.2. By Medication
9.2.3. By End Users
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
9.2.4.3. Others
9.3. Brazil Multiple Myeloma Market Outlook, 2015-2025
9.3.1. Market Size & Analysis
9.3.1.1. Revenues
9.3.2. Market Share & Analysis
9.3.2.1. By Test Type
9.3.2.2. By Medication
9.4. Argentina Multiple Myeloma Market Outlook, 2015-2025
9.4.1. Market Size & Analysis
9.4.1.1. Revenues
9.4.2. Market Share & Analysis
9.4.2.1. By Test Type
9.4.2.2. By Medication

10. Europe Multiple Myeloma Market Outlook, 2015-2025

10.1. Market Size & Analysis
10.1.1. Revenues
10.2. Market Share & Analysis
10.2.1. By Test Type
10.2.2. By Medication
10.2.3. By End Users
10.2.4. By Country
10.2.4.1. Germany
10.2.4.2. The UK
10.2.4.3. France
10.2.4.4. Italy
10.2.4.5. Spain
10.2.4.6. The Netherlands
10.2.4.7. Others
10.3. Germany Multiple Myeloma Market Outlook, 2015-2025
10.3.1. Market Size & Analysis
10.3.1.1. Revenues
10.3.2. Market Share & Analysis
10.3.2.1. By Test Type
10.3.2.2. By Medication
10.4. The UK Multiple Myeloma Market Outlook, 2015-2025
10.4.1. Market Size & Analysis
10.4.1.1. Revenues
10.4.2. Market Share & Analysis
10.4.2.1. By Test Type
10.4.2.2. By Medication
10.5. France Multiple Myeloma Market Outlook, 2015-2025
10.5.1. Market Size & Analysis
10.5.1.1. Revenues
10.5.2. Market Share & Analysis
10.5.2.1. By Test Type
10.5.2.2. By Medication
10.6. Italy Multiple Myeloma Market Outlook, 2015-2025
10.6.1. Market Size & Analysis
10.6.1.1. Revenues
10.6.2. Market Share & Analysis
10.6.2.1. By Test Type
10.6.2.2. By Medication
10.7. Spain Multiple Myeloma Market Outlook, 2015-2025
10.7.1. Market Size & Analysis
10.7.1.1. Revenues
10.7.2. Market Share & Analysis
10.7.2.1. By Test Type
10.7.2.2. By Medication
10.8. The Netherlands Multiple Myeloma Market Outlook, 2015-2025
10.8.1. Market Size & Analysis
10.8.1.1. Revenues
10.8.2. Market Share & Analysis
10.8.2.1. By Test Type
10.8.2.2. By Medication

11. Middle East & Africa Multiple Myeloma Market Outlook, 2015-2025

11.1. Market Size & Analysis
11.1.1. Revenues
11.2. Market Share & Analysis
11.2.1. By Test Type
11.2.2. By Medication
11.2.3. By End Users
11.2.4. By Country
11.2.4.1. UAE
11.2.4.2. Saudi Arabia
11.2.4.3. South Africa
11.2.4.4. Others
11.3. UAE Multiple Myeloma Market Outlook, 2015-2025
11.3.1. Market Size & Analysis
11.3.1.1. Revenues
11.3.2. Market Share & Analysis
11.3.2.1. By Test Type
11.3.2.2. By Medication
11.4. Saudi Arabia Multiple Myeloma Market Outlook, 2015-2025
11.4.1. Market Size & Analysis
11.4.1.1. Revenues
11.4.2. Market Share & Analysis
11.4.2.1. By Test Type
11.4.2.2. By Medication
11.5. South Africa Multiple Myeloma Market Outlook, 2015-2025
11.5.1. Market Size & Analysis
11.5.1.1. Revenues
11.5.2. Market Share & Analysis
11.5.2.1. By Test Type
11.5.2.2. By Medication

12. Asia-Pacific Multiple Myeloma Market Outlook, 2015-2025

12.1. Market Size & Analysis
12.1.1. Revenues
12.2. Market Share & Analysis
12.2.1. By Test Type
12.2.2. By Medication
12.2.3. By End Users
12.2.4. By Country
12.2.4.1. China
12.2.4.2. India
12.2.4.3. Japan
12.2.4.4. South Korea
12.2.4.5. South East Asia
12.2.4.6. Others
12.3. China Multiple Myeloma Market Outlook, 2015-2025
12.3.1. Market Size & Analysis
12.3.1.1. Revenues
12.3.2. Market Share & Analysis
12.3.2.1. By Test Type
12.3.2.2. By Medication
12.4. India Multiple Myeloma Market Outlook, 2015-2025
12.4.1. Market Size & Analysis
12.4.1.1. Revenues
12.4.2. Market Share & Analysis
12.4.2.1. By Test Type
12.4.2.2. By Medication
12.5. Japan Multiple Myeloma Market Outlook, 2015-2025
12.5.1. Market Size & Analysis
12.5.1.1. Revenues
12.5.2. Market Share & Analysis
12.5.2.1. By Test Type
12.5.2.2. By Medication
12.6. South Korea Multiple Myeloma Market Outlook, 2015-2025
12.6.1. Market Size & Analysis
12.6.1.1. Revenues
12.6.2. Market Share & Analysis
12.6.2.1. By Test Type
12.6.2.2. By Medication
12.7. South East Asia Multiple Myeloma Market Outlook, 2015-2025
12.7.1. Market Size & Analysis
12.7.1.1. Revenues
12.7.2. Market Share & Analysis
12.7.2.1. By Test Type
12.7.2.2. By Medication

13. Global Multiple Myeloma Market Policies, Regulations, Product Standards14. Global Multiple Myeloma Market Trends & Insights

15. Global Multiple Myeloma Market Dynamics

15.1. Growth Drivers
15.2. Challenges
15.3. Impact Analysis

16. Global Multiple Myeloma Market Hotspot & Opportunities17. Global Multiple Myeloma Market Key Strategic Imperatives for Success & Growth

18. Competition Outlook

18.1. Competition Matrix
18.1.1. Product Portfolio
18.1.2. Target Markets
18.1.3. Target End Users
18.1.4. Research & Development
18.1.5. Strategic Alliances
18.1.6. Strategic Initiatives
18.2. Company Profiles of top companies (Business Description, Product Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
18.2.1. Janssen Biotech
18.2.2. Bristol-Myers Squibb
18.2.3. Novartis
18.2.4. Celgene
18.2.5. Kesios Therapeutics
18.2.6. Amgen
18.2.7. Sanofi Genzyme
18.2.8. Juno Therapeutics
18.2.9. Takeda
18.2.10. Karyopharm

19. Disclaimer